Evaluation of Almitrine Infusion During Veno-Venous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome in Adults

Anesth Analg. 2019 Aug;129(2):e48-e51. doi: 10.1213/ANE.0000000000002786.

Abstract

This single-center case series investigated the effect of almitrine infusion on PaO2/fraction of inspired oxygen (FIO2) in 25 patients on veno-venous extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. A positive trial was defined as an increase of PaO2/FIO2 ratio ≥20%. Thirty-two trials were performed. Twenty (62.5%, 95% confidence interval, 37.5%-75%) trials in 18 patients were positive, with a median PaO2/FIO2 ratio increase of 35% (25%-43%). A focal acute respiratory distress syndrome and inhaled nitric oxide therapy were more frequent in patients with a positive response to almitrine. We observed no complications of almitrine use.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Almitrine / administration & dosage*
  • Almitrine / adverse effects
  • Extracorporeal Membrane Oxygenation* / adverse effects
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Recovery of Function
  • Respiration / drug effects*
  • Respiratory Distress Syndrome / diagnosis
  • Respiratory Distress Syndrome / physiopathology
  • Respiratory Distress Syndrome / therapy*
  • Respiratory System Agents / administration & dosage*
  • Respiratory System Agents / adverse effects
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Respiratory System Agents
  • Almitrine